May 2022 in “European medical journal” An 11-year-old girl with a hair-pulling disorder had a hairball in her stomach and was treated with medication, therapy, and a team of doctors.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
GLP-1 receptor agonists increase the risk of hair loss, mainly due to weight loss-related nutrient deficiency.
July 2024 in “Reactions Weekly” February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
1 citations
,
December 2014 in “Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology” Adding aripiprazole to the treatment improved hair-pulling symptoms in a teenager.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
October 2025 in “The American Journal of Gastroenterology” Early diagnosis and treatment of hair ingestion in children can prevent serious health issues.
March 2024 in “Authorea (Authorea)” Using lyopreserved umbilical tissue allograft may improve healing and reduce recurrence of pilonidal cysts.
2 citations
,
January 2023 in “Journal of Education, Health and Sport” Cognitive-behavioral therapy with habit reversal training is the most effective treatment for trichotillomania.
September 2024 in “Pediatrics in Review” A trichobezoar caused the girl's recurrent intussusception, and surgery plus psychiatric therapy resolved her symptoms.
78 citations
,
June 2005 in “Annals of oncology” Cetuximab can cause excessive eyelash growth.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
December 1951 in “Journal of the American Medical Association” Propylthiouracil treatment can cause hair loss.
January 2024 in “Wiadomości Lekarskie” New technologies improve diagnosis and treatment of digestive disorders.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
October 2024 in “Journal of Advanced Pharmaceutical Technology amp Research” Trigonelline nanocrystal cream effectively promotes hair growth and may reduce side effects.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.